Cargando…
Early start and stop of biologics: has the time come?
Despite considerable advances in the management of rheumatoid arthritis, results are still not satisfactory for all patients. The treatment goal in rheumatoid arthritis is remission, and there currently are numerous conventional and biological medications available to reach this aim. There are also...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915229/ https://www.ncbi.nlm.nih.gov/pubmed/24502187 http://dx.doi.org/10.1186/1741-7015-12-25 |
_version_ | 1782302548352303104 |
---|---|
author | van Vollenhoven, Ronald F Nagy, György Tak, Paul P |
author_facet | van Vollenhoven, Ronald F Nagy, György Tak, Paul P |
author_sort | van Vollenhoven, Ronald F |
collection | PubMed |
description | Despite considerable advances in the management of rheumatoid arthritis, results are still not satisfactory for all patients. The treatment goal in rheumatoid arthritis is remission, and there currently are numerous conventional and biological medications available to reach this aim. There are also different treatment strategies but with only limited comparative evidence about their efficacies. More patients now achieve remission while on treatment, but it remains elusive in the majority of patients. Treatment-free remission, the ultimate goal of therapy, is only achieved in very few patients; even when this happens, it is most likely due to the natural course of the disease rather than to any specific therapies. Modern treatment is based on the initiation of aggressive therapy as soon as the diagnosis is established, and on modifying or intensifying therapy guided by frequent assessment of disease activity. In this commentary we will discuss the current treatment paradigm as well as the possibility of an induction-maintenance regimen with biological disease-modifying antirheumatic drugs in early rheumatoid arthritis. |
format | Online Article Text |
id | pubmed-3915229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39152292014-02-13 Early start and stop of biologics: has the time come? van Vollenhoven, Ronald F Nagy, György Tak, Paul P BMC Med Commentary Despite considerable advances in the management of rheumatoid arthritis, results are still not satisfactory for all patients. The treatment goal in rheumatoid arthritis is remission, and there currently are numerous conventional and biological medications available to reach this aim. There are also different treatment strategies but with only limited comparative evidence about their efficacies. More patients now achieve remission while on treatment, but it remains elusive in the majority of patients. Treatment-free remission, the ultimate goal of therapy, is only achieved in very few patients; even when this happens, it is most likely due to the natural course of the disease rather than to any specific therapies. Modern treatment is based on the initiation of aggressive therapy as soon as the diagnosis is established, and on modifying or intensifying therapy guided by frequent assessment of disease activity. In this commentary we will discuss the current treatment paradigm as well as the possibility of an induction-maintenance regimen with biological disease-modifying antirheumatic drugs in early rheumatoid arthritis. BioMed Central 2014-02-06 /pmc/articles/PMC3915229/ /pubmed/24502187 http://dx.doi.org/10.1186/1741-7015-12-25 Text en Copyright © 2014 van Vollenhoven et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary van Vollenhoven, Ronald F Nagy, György Tak, Paul P Early start and stop of biologics: has the time come? |
title | Early start and stop of biologics: has the time come? |
title_full | Early start and stop of biologics: has the time come? |
title_fullStr | Early start and stop of biologics: has the time come? |
title_full_unstemmed | Early start and stop of biologics: has the time come? |
title_short | Early start and stop of biologics: has the time come? |
title_sort | early start and stop of biologics: has the time come? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915229/ https://www.ncbi.nlm.nih.gov/pubmed/24502187 http://dx.doi.org/10.1186/1741-7015-12-25 |
work_keys_str_mv | AT vanvollenhovenronaldf earlystartandstopofbiologicshasthetimecome AT nagygyorgy earlystartandstopofbiologicshasthetimecome AT takpaulp earlystartandstopofbiologicshasthetimecome |